ap 745

World Animal Health and Nutrition News

No 745 9th November 2012 www.animalpharmnews.com

o n l i n e d a i l y

FMD vaccines lift China Animal Health

9

ASAS One Health challenge

Page 14

Major Q3 company financials

Pages 3-5

Stray dogs and zoonoses spread

Page 10-11

Hendra vaccine commercialized in Australia by PfizerA vaccine against the deadly Hendra horse virus has been launched in Australia. The introduction of the Equivac HeV vaccine comes after a collaborative effort between Pfizer Animal Health and Australian and US animal health laboratories.

Available under permit from accredited Australian veterinarians, the vaccine will assist in breaking the cycle of transmission that also puts humans at risk of contracting this potentially lethal virus. The Hendra virus has caused the deaths of 81 horses since its discovery in 1994, 30 of which died since 2011. There have been four human fatalities since 1994, the most recent in 2009.

With no known cure for Hendra, the Equivac HeV vaccine is positioned to become the most effective defense against the virus. While the prevalence is low, the Hendra virus is one of Australia’s most lethal viruses with 75% of horses infected with the virus dying as a result of the disease, usually within the first two days of showing signs of illness.

In Australia, Pfizer Animal Health has worked in partnership with CSIRO’s Australian Animal Health Laboratory. Additionally, US organizations, the Uniformed Service University of the Health Sciences and The Henry M Jackson Foundation for the Advancement of Military Medicine have also contributed to the development of the vaccine.

“Equivac HeV vaccine exemplifies the scientific expertise and world-class facilities that we have access to here at Pfizer in Australia,” said Mike van Blommestein, division director, Pfizer Animal Health Australia.

“By investing in the development of innovative medicines and vaccines, we are not only supporting the local research and development industry, but also ensuring we can respond rapidly to emerging infectious diseases in Australia such as the Hendra virus.”

Pfizer Australia also managed the formal regulatory approval process including safety and efficacy trials required by the Australian Pesticides

and Veterinary Medicines Authority for the granting of permit approval, as well as fulfilling the requirements of the Australian Quarantine and Inspection Service.

Leading the specialist team from the Australian Animal Health laboratory, Dr Deborah Middleton, veterinary pathologist, said Australian researchers had a deep understanding of the need for an equine vaccine to aid in the prevention of the spread of Hendra virus.

“As a veterinarian, I have seen first-hand how Hendra has created difficult working conditions for my colleagues and any Australian who works with horses,” said Dr Middleton. “A horse vaccine is crucial to breaking the cycle of Hendra virus transmission from flying foxes to horses and then to people, as it can prevent both the horse developing the disease and passing it on. For the first time, we have a Hendra specific tool that provides veterinarians with a greater level of safety when they come into contact with sick horses.” l

Product Development and Regulatory Affairs

GAB Consulting

9 November 2012 l Animal Pharm www.animalpharmnews.com

2

Contents

Five Minute PharmIf you can only spare five minutes ...Animal Pharm leads this issue with the news that a vaccine against the deadly Hendra horse virus has been launched in Australia. The introduction of Equivac HeV vaccine comes after a collaborative effort between Pfizer Animal Health and Australian and US animal health laboratories. Available under permit from accredited Australian veterinarians, the vaccine will assist in breaking the cycle of transmission that also puts humans at risk of contracting this potentially lethal virus.

Third quarter company results are to fore at this time of the year, with market leader Pfizer Animal Health’s latest figures showing a 2% year-on-year drop in revenues during Q3. Animal health sales reached approximately $1.02 billion, which also represented a 6% decrease on foreign exchange rates.

Meanwhile, Merck’s animal health division has reported a 1% fall in Q3 revenues, which it attributes to foreign currency effects. The business has reported third-quarter sales of $815 million, 1% down on the $826m in Q3 2011. The company said there was an 8% negative impact from foreign exchange factors during the period.

Third quarter financial results from German firm Bayer Animal Health show a 20.6% increase in sales to €340 million ($440 million) from the €282m recorded in Q3 2011. The increase is 11.3% when measured at constant currencies. Elanco posted a 6% rise to $479.4m in Q3, although this is a slowing from the 32% growth rate reported at H1 this year.

Swiss firm’s Novartis Animal Health’s financial performance continues to be dogged by the suspension of production at the parent company’s consumer Health plant in Lincoln, Nebraska, since the beginning of 2012. The firm’s animal health business is consolidated into the larger consumer health unit, which reported Q3 revenues of $938 million (a 22% drop on the same period in 2011). Consumer Health’s core operating income fell from $228m in Q3 2011 to $77m this time around.

US healthcare products distributor Henry Schein is set to make its third acquisition of the year by acquiring Irish firm C&M Vetlink. Henry Schein has signed a definitive agreement to buy C&M, which is a leading distributor of animal health products in Ireland, for an undisclosed fee.

Brazil has finally opened a registration process for generic animal health products in this large country market, while in Europe, the Schmallenberg virus of ruminant animals has been confirmed as far west as Ireland.

Research in Denmark has found that modern robot milking systems do not produce more cases of mastitis or other udder infections than traditional milking methods. The head of the Danish Biosens dairy research project Jens Yde Blom told the recent British Mastitis Conference in Worcester that there has been no increase in mastitis incidence rates since automated milking was introduced into the country.

Our Asia Editor Malcolm Flanagan digs deep into the growing problem of dealing with millions of roaming stray dogs around the world and their many diseases. Experts attending a major international dog population conference held in UK gathered to hear that of the 500-700 million dogs worldwide 75% are free-roaming. Many of these dogs carry diseases such as echinococcosis, leishmaniasis and rabies and are in poor health. Speakers stressed that stray dog population management is an integral part of programs aimed at reducing the risk of dog-based zoonoses, with rabies being the most widespread.

And finally, US animal health consultant Mick Wells explains what it is like to leave a comfortable job with a major animal health company to strike out as independent consultant.

Companies

Hendra vaccine commercialized in Australia by Pfizer 1

Merial records 4% growth in Q3 3

Currency impact hits Merck/MSD 3

Nebraska slows Novartis as Q3 suffers 3

Mixed Q3 results for Pfizer Animal Health 3

Vétoquinol 8.4% ahead at Q3 4

Avacta posts 23% revenue growth 4

AXA gives Ceva $130m funding fillip 4

Orion recovers with 25% growth in Q3 4

Elanco growth slows in third quarter 5

Bayer Q3 sees 21% revenue rise 5

MWI to distribute Abaxis diagnostics 5

Products

New milk-based bovine pregnancy test 6

Ready-to-use Cefenil launched 6

Merial online with deworming tool 6

Canada approves Bayer antimicrobial 6

New Japanese products 6

Research

Bee bite contains useful anesthetic 8

DSM, Merial work on algal vaccines 8

Robot milking does not increase mastitis incidence 8

Pfizer offers grants for swine research 8

People 9

Feature

Growing stray dog problem encourages zoonotic disease 10-11

Feature

Commercial success seen as part of One Health 11

Feature Why I became an

independent animal health consultant 12-13

Americas

Responding to the ASAS animal health challenge 14

Harrisvaccines secures another US vaccine contract 15

US maintains funding for FAO avian flu work 15

Brazil opens registration for generics 15

Europe

New veterinary school for the UK 16

First SBV case in Ireland 16

Schmallenberg discovered in Finnish cattle 16

Newcastle disease detected in Romania 16

Sharp fall in UK antimicrobial sales 17

Henry Schein makes Irish buy 17

UK horse found with EIA 17

World

PPR threat sparks new vaccine bank 18

Canada, Russia harmonize vet certificates 18

Australia acts on biosecurity breach 18

Dubai ruminant strategy working 18

FMD vaccines boost China Animal Healthcare revenue 19

First Leman pig conference in China 19

Alltech in research pact with China 19

Diary 20

Buyer’s Guide 20

Recruitment 24

Companies

www.animalpharmnews.com 9 November 2012 l Animal Pharm

3

Merial records 4% growth in Q3Merial was unable to match its good performance in Q2 with a 4% increase in third-quarter revenues, compared to the 9% gain made during the previous three months..

Third-quarter revenues were €519 million ($675 million). The company was given a major boost by its performance in emerging markets – sales climbed by 21% to €140m. Revenue from the firm’s companion animals segment went up 3% year-on-year to €330m due to a double-digit-sales increase from the heartworm preventative Heartgard in the US.

However, the company was set back by a 4% decrease in sales of its Frontline/fipronil family of products. The product line made good gains in Western Europe (+8% to €42m) and emerging markets (24% to €26m) but suffered a 4% decline in sales

in the US, where revenues reached €178m. Merial said it was impacted by competitive pressure in the US.

Merial’s Production Animals division posted sales of €189m, which was a 5% increase on the third quarter of 2011. Production Animals was boosted by gains made by the company’s Veterinary Public Health segment (+46%) and the Swine segment (+22%). Merial said that the Veterinary Public Health segment benefited from sales of Foot-and-Mouth vaccines following outbreaks in emerging markets.

Merial, a subsidiary of Sanofi, outperformed its parent company during the third quarter. Sanofi suffered a 3% dip in sales to around €9 billion because one of its lead products, Eloxatin, came off patent and faced increased competition in the US. l

Novartis Animal Health’s financial performance continues to be dogged by the suspension of production at the parent company’s Consumer Health plant in Lincoln, Nebraska since the beginning of 2012.

The firm’s animal health business is consolidated into the larger consumer health unit, which reported Q3 revenues of $938 million (a 22% drop on the same period in 2011). Consumer Health’s core operating income fell from $228m in Q3 2011 to $77m this time around.

The voluntary closure of the Lincoln manufacturing plant over packaging problems with a line of human health pharmaceuticals has been impacting Novartis’ animal health performance throughout the year (Animal Pharm, July 24).

A Novartis spokesperson told Animal Pharm that, outside

the brands produced at the Lincoln facility, global growth was “very good”. The company enjoyed strong performances during the first nine months of the year in Germany/Austria, France and Japan, as well as in emerging markets such as China, India, Russia and Brazil.

A highlight from the firm’s product portfolio was oral antibiotic Denagard in the food-producing animals business, which witnessed strong sales growth. In the companion animal business, fly control product Agita, feline topic dermatitis treatment Atopica and the Capstar flea product also performed well.

Like its animal health subsidiary, the Novartis group was unable to post revenue growth for the quarter. Novartis made $13.8bn of sales during Q3, a 7% decline year-on-year. lCurrency impact hits

Merck/MSDMerck’s animal health division (Merck Animal Health in the US and Canada, MSD Animal Health everywhere else) has reported a 1% fall in Q3 revenues, which it attributes to foreign currency effects.

The business has reported third-quarter sales of $815 million in the three months ended September 30th 2012, 1% down on the $826m in Q3 2011. The company said there was an 8% negative impact from foreign exchange factors during the period.

Excluding these, there was growth in the cattle, poultry and companion animal segments of the business. The Animal Health division

launched the Activyl (Indoxacarb) line of flea and tick products in the US in June, following its appearance on the EU market earlier in the year, which the company said is an important addition to its companion animal portfolio.

Nine months into the current financial year, Animal Health revenues stand at $2.501 billion, a 5% increase on the $2.385bn at the same stage of the 2011 year.

Merck as a whole has reported a net income of $1.73bn on revenues of $11.49bn in Q3, compared to $1.69bn and $12.02bn in the third quarter of 2011. l

Pfizer’s animal health business recorded a 2% year-on-year drop in revenues during the third quarter.

Animal health sales reached approximately $1.02 billion, which also represented a 6% decrease on foreign exchange rates.

Pfizer stated that its animal health unit reported sales that were 4% up operationally in comparison with the third quarter of 2011, mainly due to increased demand across its companion animal and global livestock portfolios in key geographies.

Despite the reverse, the animal health business managed to outperform the wider Pfizer group significantly during the third quarter. Pfizer’s overall revenues plummeted 16% to $13.97bn compared to the previous year due to the loss of exclusivity of its Lipitor drug since November 2011.

Over the first nine months of 2012, the animal health side of the business has only recorded a 2% increase in sales to $3.13bn. This is a 6% rise operationally but a 4% dip on foreign exchange rates. l

Nebraska slows Novartis as Q3 suffers

Mixed Q3 results for Pfizer Animal Health


4

Companies

Finnish pharma firm Orion has witnessed a 25% growth in animal health revenues in Q3.

Animal health sales for the period reached €17.5 million ($22.8 million), helping the division offset a 1% dip in revenue during the first half of the year (Animal Pharm, August 2).

Overall, the animal health unit reported a 7% increase in sales to €52m during the period January through September.

The Espoo-based company

said sales of its animal sedatives at €16m accounted for 32% of the division’s net sales during these nine months. This range of sedatives includes Dexdomitor (dexmedetomidine), Domitor (medetomidine), Domosedan (detomidine) and Antisedan (atipamezole).

Despite these revenue gains – matched by the company’s core pharmaceutical business – Orion forecasts flat profit levels for 2012 (Animal Pharm, October 10). l

Vétoquinol 8.4% ahead at Q3The French animal health business Vétoquinol has reported an 8.4% increase in revenues for the third quarter of its financial year.

The company generated Q3 sales of €74.1 million, an 8.4% increase on the €68.4m in the same period of 2011, or 5.0% at constant exchange rates. Over the same period, the company says its sales growth resumed in Europe, which is the Group’s largest geographic market. This was enhanced by a significant contribution from new product launches over the past two years, including Cimalgex, Ceftiocyl, Forcyl and Flevox.

Nine months into the financial year, revenues stand at €220.9m, a 6.2% increase on the €208.1m from the first three quarters of the previous year. Like-for-like growth, which was 1.9% at the end of Q1 2012, had risen to 2.9% by the end of September.

Vétoquinol says sales were lifted by double-digit growth in the Asia Pacific region (12.8%) and the Americas (19.3%). It also reports that sales of its Marbocyl antimicrobial product, which had suffered from generic competition in Europe recently, have stabilized.

“The strong performance achieved over the first 9 months of the year confirms the Group’s return to growth,” commented Vétoquinol chief executive Matthieu Frechin. “The integration of our new subsidiary, Orsco Laboratoire Vétérinaire (Animal Pharm, September 27) is progressing according to plan. Thanks to our strong financial structure, we can continue to review targeted acquisitions in line with our strategy. We also confirm our intention to bolster sales growth and earnings in the short and medium term.” l

Avacta posts 23% revenue growth UK analytical and diagnostic technology developer Avacta has reported a strong fiscal 2012 with good growth from its animal health division.

During the fiscal year ending July 31 2012, the Group’s veterinary diagnostics unit posted revenue growth of 23% to £1.49 million ($2.4 million). This was principally due to increased export business.

One potential thorn in Avacta’s side has been removed. Its lead product in the animal health division, the AX.1 point-of-care immunoassay system, previously had a delayed launch due to manufacturing

problems (Animal Pharm, August 28). The company said that these issues have been resolved and the first units of AX.1 have been placed.

Avacta’s total sales for the fiscal year reached £3.13m, up 28% on the previous year. The firm’s operating loss widened from £1.1m in 2011 to £1.6m this year.

The firm’s chief executive, Alastair Smith, said: “Despite a challenging economic backdrop we have seen solid commercial progress in the year. Avacta is in a strong position and funded to deliver product development over the next couple of years.” l

Orion recovers with 25% growth in Q3

Global animal health company Ceva Santé Animale is to receive €100 million ($130 million) in funding from AXA Private Equity, one of Europe’s leading private equity firms.

Ceva said that this flexible bond financing line will allow it to enter the next phase of development and pursue its international build-up strategy.

Marc Prikazsky, Ceva chairman and chief executive, said: “Our ability to successfully incorporate new companies and products into a wider strategic vision has been a key element for the growth of Ceva. Our results-based culture has allowed numerous entrepreneurs to join us and retain their own management styles while pursuing the same global vision as the group.”

This deal follows AXA’s previous equity investment in Ceva in 2007, when it provided €30m funds. Ceva’s

majority shareholders are its own management team after a buy-out, which also occurred in 2007. Other stakeholders are French private equity businesses Nixen and Sagard, as well as French mezzanine fund Euromezzanine.

In Ceva’s most recent financial results (first half 2012), the company recorded strong growth rates internationally. Growth was above 30% in North America and Asia-Pacific, and over 10% in central and Eastern Europe (including Turkey), Africa and the Middle East (Animal Pharm, July 25).

In a recent interview with Animal Pharm, Ceva’s chief executive of North American operations, Craig Wallace, said the firm was involved in conversations related to potential partnerships with various start-ups within the US animal health industry (Animal Pharm, October 8). l

AXA gives Ceva $130m funding fillip


5

California-based veterinary diagnostics company Abaxis has entered into a definitive distribution agreement with MWI Veterinary Supply.

Abaxis develops, manufactures, markets and sells portable blood analysis systems for use in any veterinary care setting to provide clinicians with rapid blood constituent measurements.

MWI will warehouse, market and promote the full line of Abaxis veterinary products throughout the US. The agreement starts at the beginning of next year.

Clint Severson, Abaxis president and chief executive commented: “We welcome MWI to the Abaxis external organization and look forward to their incremental contributions to our business and their own.

“I would also at this time like to reinforce and emphasize our commitment to our existing roster of distributor partners. Abaxis will continue to work hard in supporting its efforts in continuing to build and strengthen our mutual businesses.” l

MWI to distribute Abaxis diagnostics

Bayer Q3 sees 21% revenue riseThird quarter financial results from Bayer Animal Health show a 20.6% increase in sales to €340 million ($440 million) from the €282m recorded in Q3 2011.

The increase is 11.3% when measured at constant currencies. Animal Health trading figures are consolidated into the Consumer Health segment of Bayer’s Healthcare division.

Nine months into its current financial year, Animal Health sales are €1.019 billion, a 12.7% increase on the €904 million at the same stage of fiscal 2011 or 6.3% higher at constant currencies. The Q3

figures follow a 9.2% (4%) increase in first half revenues (Animal Pharm, August 2)

The Advantage (imidacloprid) line of companion animal antiparasitics is Consumer Health’s second best selling product. The line had a 37.4% increase in sales for the latest quarter at €125m, while cumulative revenues for the first three quarters were 19.9% up against the previous year at €403m. The company commented that Advantage sales were higher against a weak prior-year quarter, mainly due to sales gains in North America and successful marketing. l

Elanco growth slows in third quarterElanco Animal Health, the veterinary products division of Eli Lilly & Co, has reported 6% revenue growth in fiscal Q3, against an 11% loss by the parent company.

Despite this healthy growth, Q3 did not match the animal health division’s performances posted during the first half of the year. In Q1, Elanco posted a 33% year-on-year gain in revenues (Animal Pharm, April 25), while in the second quarter sales went up by 32% (Animal Pharm, July 27).

Elanco had global animal health product sales of $479.4 million in the third quarter of 2012, a 6% increase on the $451m from the same period of 2011. The quarter saw US sales grow by 16% to $275.3m, due primarily to increased demand for the company’s companion animal products.

However, sales outside the US decreased by 4% to $204.1m.

Elanco said the negative effect of foreign exchange rates and lower product prices was partially offset by increased sales volumes. Revenue growth in certain markets outside of the US was adversely affected by the ongoing difficult economic conditions.

Cumulative Elanco sales in 2012 so far are $1.48 billion, 22% higher than the $1.21bn at the nine month-stage of fiscal 2011. Lilly said it expects “strong double digit revenue growth” from Elanco for the full 2012 year.

Eli Lilly Q3 net income, at $1.33bn, is 7% up on Q3 2011, but revenues are 11% lower at $5.44bn. This follows the patent expiration of Zyprexa, a human psychosis treatment which is Lilly’s fifth highest selling product. Sales of Zyprexa alone fell by 68% to $374.5m in the quarter. l

• Efficacy and Safety studies

• GLP or GCP compliant studies

• GLP accredited animal accomodation

• World leading Parasitology expertise :gut roundworm infections, liver fluke,

protozoan parasites, ectoparasites

• Studies in all species of livestock

We are highly experienced in conductinga wide range of studies to the appropriate

regulatory requirements – get in touchto learn how we can help you meet your

product development goals.

Anti-parasitic Research& Testing Services

Please contact: +44 131 445 [email protected] www.moredun-scientific.com

88 x 128mm portrait-1_Layout 1 31/10/2012 11:41 Page 2


6

Products

New milk-based bovine preg test IDEXX Laboratories has launched the first milk-based pregnancy test designed to optimize reproductive efficiency in dairy herds.

IDEXX Milk Pregnancy Test is an ELISA-format test that detects pregnancy-associated glycoproteins (PAGs) in order to determine the pregnancy status of a cow while minimizing the need for animal handling.

Westbrook, Maine-based IDEXX said that the test has a high level of sensitivity and specificity from 35 days post breeding and 60 days post calving. The test allows producers to work with dairy herd improvement (DHI) organizations to get accurate confirmation of open cows in less than 3.5 hours.

“Expanding the use of DHI milk samples to include

confirmation of pregnancy is a simple, cost-effective way for producers to increase the efficiency of their total operation,” said Olivier te Boekhorst, vice president and general manager of IDEXX Livestock and Poultry Diagnostics.

“At the same time, the IDEXX Milk Pregnancy Test also helps recording laboratories make their herd health management programs more attractive to their customers.”

IDEXX will be hoping that the new product will help boost sales from its livestock division. Last week, the firm reported a 5% increase in Q3 sales. However, this was mainly due to gains made by its companion animals division – its livestock unit reported a 9% dip in sales (Animal Pharm, October 19). l

Pfizer Animal Health has launched Simplicef Tablets (cefpodoxime proxetil) for the treatment of bacterial skin infection in dogs onto the Japanese market. Simplicef is the first oral once-daily antibiotic based on the third generation cephalosporin, and has a wide spectrum of efficacy against both gram positive and negative bacteria,

including Staphylococcus, Streptococcus, E coli and Proteus mirabilis.

Eli Lilly Japan has recently obtained Japanese Ministry of Agriculture, Fisheries and Food (JMAFF) approval for its Comfortis (spinosad) product for the removal of fleas from cats. Comfortis has already been approved in Japan for the treatment of fleas and ticks on dogs. l

Bayer Animal Health’s Baytril 100 (enrofloxacin) injectable solution has been approved in Canada for use against swine respiratory disease (SRD).

Baytril 100 is bactericidal and designed to rid swine of Actinobacillus pleuropneumoniae, Pasteurella multocida and Haemophilus parasuis – the main pathogenic bacteria associated with SRD.

According to Bayer, the product delivers therapeutic drug concentrations to lung tissues within two hours of a single subcutaneous dose.

Baytril has been available to veterinarians since 2004 for treating recurring respiratory disease in high-risk feedlot cattle. Recently, Bayer launched an updated version of its Baytril antibiotic for pigs in Europe (Animal Pharm, October 17). l

Ready-to-use Cefenil launchedNorbrook Laboratories has launched its Cefenil (ceftiofur) antibiotic in a ready-to-use suspension formulation in the UK and Eire markets.

Cefenil RTU is a 50mg/ml broad spectrum injectable suspension for cattle and swine. It is indicated for the treatment of bacterial respiratory disease, foot rot and acute post-partum metritis in cattle and bacterial respiratory disease in swine.

Norbrook’s Cefenil Powder and Solution for Injection has been available for a number of years for the treatment of cattle and swine and has recently been indicated for the treatment of BRD in horses in the UK. The company said that Cefenil RTU offers vets

an additional choice in the treatment of BRD.

“Cefenil is a tried and tested antibiotic which vets have been using for a number of years,” said Dr Barry McInerney, Norbrook’s GB veterinary advisor.

“We are delighted to extend the Cefenil range with a RTU suspension for cattle and pigs and adding an indication for horses to our Cefenil Powder and Solution for Injection.

“It gives vets a wider choice for the treatment of BRD with a product with which they are already familiar. It also offers a zero-milk withhold and a 5-day meat withhold, which is the shortest on the market.” l

Canada approves Bayer antimicrobial

New Japanese products

Merial has launched a new website designed to provide US cattle producers with digital deworming assistance – www.TruthAboutDeworming.com.

The website gives users instant evaluations of their current deworming protocols. “Treating cattle for parasites provides the greatest economic return of any animal health practice, according to Iowa State University researchers,” the site claims.

Merial states that dewormers do not work long enough to prevent reinfection by

parasites. “Until a true long-acting product becomes available, a more strategic, timed approach to deworming is the best solution,” the website reads.

Users will be asked questions regarding herd size, pasture turnout plans, location of cattle and current parasite control protocol and schedule. The online tool will then be able to predict the overall health of a herd in a format that can be used to evaluate overall herd productivity and to improve strategies for cleaner cattle and pastures. l

Merial online with deworming tool

Research


8

Bee bite contains useful anestheticA European research consortium has discovered that the bite of the honeybee contains a natural anesthetic which could be used in treating animals and humans.

Scientists at the UK honey bee research specialist Vita, along with Greek and French counterparts, made the discovery that bees can bite as well as sting.

The anesthetic contained in the bite may not only help honeybees fend off pests such as wax moth and the parasitic varroa mite but it also has potential for use in animal and human medicine.

The surprise findings could lead to a complete re-thinking of honeybee defense mechanisms and could lead to the production of a natural,

low toxicity local anesthetic.

The natural anesthetic compound measured at the University of Athens is 2-heptanone (2-H), a natural compound found in many foods and also secreted

by certain insects, but never before understood to have

anesthetic properties. Independent tests have

verified Vita’s findings and the potential of 2-heptanone as a local anesthetic.

Vita has already patented the compound for use as a local anesthetic and is seeking pharmaceutical partners to develop it further.

The new research clearly shows that 2-heptanone paralyses small insects and mites bitten by bees for up to nine minutes. l

Pfizer Animal Health is calling for continued research into the clinical efficacy of Draxxin (tulathromycin) Injectable Solution, a macrolide for the treatment of swine respiratory disease (SRD).

The firm will provide up to four grants, totaling $100,000, for research proposals focused on its product as part of the

overall treatment of SRD. Pfizer said all applicants must be current university staff, advanced study students at universities or practicing doctors of veterinary medicine.

Pfizer will provide Draxxin to the successful applicants at no cost. The deadline for proposals is November 15. l

DSM Nutritional Products, a subsidiary of global life sciences firm Royal DSM, will collaborate with Merial to develop animal health vaccines using an algal expression technology.

According to DSM, the use of its algal expression system could offer a faster and more efficient production method for producing animal health vaccines.

“We are pleased to join with Merial on this important project that we expect will validate the algal expression system as a viable alternative to egg or cell culture-based vaccines, which would offer important benefits for animal vaccine production,” said Peter Nitze, president of the

Nutritional Lipids division within DSM Nutritional Products.

Under the terms of the agreement, Merial will provide R&D funding to DSM to support the development of animal vaccine antigens using the algal expression system. DSM is also eligible to earn milestone payments, license fees and royalties on potential product sales.

If a commercially successful vaccine results from this collaboration, both companies will either enter into a commercial supply agreement for the production of the vaccine antigen or DSM will receive a technology transfer fee to convey the manufacturing rights to Merial. l

DSM, Merial work on algal vaccines

Research in Denmark has found that modern robot milking systems do not produce more cases of mastitis or other udder infections than traditional milking methods.

The head of the Danish Biosens dairy research project Jens Yde Blom told the recent British Mastitis Conference in Worcester that there has been no increase in mastitis incidence rates since automated milking was introduced into the country.

“Overall, there are few indications of general health problems on conversion to robotic milking. Individual farms often have their unique problems. These appear to be related to management, expectations and facilities rather than the milking system,” said Mr Blom.

“Fertility has not been affected. Breeding success might be more difficult or lactations may have been

extended with automated milking as the time to conception and calving might be lengthening. These are not primary health issues that affect the well being of the cow.”

He also mentioned that there had been a small number of lameness issues or ‘locomotion sores’ in Denmark, the Netherlands and the UK as a result of robotic milking.

Mr Blom said that from his results it was clear that Danish farmers were happy with automatic milking because it left them time to do other work on the farm and spend more time with their families.

So far no adverse effects to their herds had been observed. Automated milking has been in operation in Denmark since the late nineties and some 900 dairy sites use robotic equipment to milk around 520,000 cows. l

Robot milking does not increase mastitis incidence

Pfizer offers grants for swine research


9

People

The New Zealand veterinary authorities are to merge the country’s Animal Health Board (AHB) and its National Animal Identification and Tracing (NAIT) scheme that came into effect in July this year.

William McCook, current chief executive of the Animal Health Board has been appointed chief executive of the merged organization after an open and competitive selection process. Russell Burnard continues in his role as chief executive of NAIT, until the merger completes in July 2013.

Jeff Grant, the chairman of the new organization’s board, said that the first task for the board and chief executive is to plan and implement the merger of the AHB and NAIT. Operationally, its immediate focus will be sustaining the success of the country’s bovine TB strategy and completing implementation of the NAIT scheme.

“We recognize the opportunity to apply and extend the abilities of the two existing organizations to other programs which will benefit and sustain New Zealand’s primary industries,” he said.

China Animal Healthcare as appointed Steven Yan Qing Ma to the position of non-executive director.

Mr Ma is currently managing director and head of Beijing for Chinese private equity firm Themes Investment Partners. Before joining Themes in 2011, Mr Ma worked for the Carlyle Group.

Here he focused on investing in Chinese technology, media and consumer industries.

Prior to his position at the Carlyle Group, he held positions at Colony Capital and Lazard Freres.

China Animal Healthcare’s executive directors are Wang Yangang (chairman and chief executive) and Sun Jinguo (deputy chief executive), while its other non-executive director is Fu Shan.

The company also has three independent non-

executive directors: Ong Kian Guan, Feng Jinglan and Wong Gang.

The firm specializes in the manufacture, sale and distribution of 452 compound chemical drugs and 44 biological drugs for poultry and livestock in China. The group also produces 37 feed additive products.

The company sells to around 4,900 animal drug retailers and 32 large poultry enterprises in China and through government tenders to various regional government animal disease control centers.

Animal Health Board China Animal Healthcare

Kansas-based companion animal drug development firm Aratana Therapeutics has employed Louise Mawhinney as its chief financial officer.

This is a newly-created role for the firm and comes as part of an expansion of its senior management.

This included the recent appointment of Steven St Peter to the role of chief executive (Animal Pharm, September 13).

Ms Mawhinney has more than 15 years of experience as a chief financial officer. She has previously worked for molecule sequencing firm Helicos BioSciences and cancer therapy company ArQule.

Mr St. Peter said: “Louise is a very experienced and dynamic executive who is well known within the biotech community. I had the pleasure of working with Louise when she helped complete Helicos’ initial public offering during my tenure as a member of the board.”

Aratana

UK veterinary drug developer Dechra Pharmaceuticals has added Tony Griffin as an executive director.

Mr Griffin was previously the chief executive of Eurovet Animal Health, which Dechra purchased earlier this year (Animal Pharm, April 3). He was also the chief executive of Dutch veterinary pharmaceutical

company AUV Holding. Following Dechra’s acquisition of Eurovet, Mr Griffin joined as managing director of Dechra Veterinary Products Europe.

“He brings with him a wealth of market knowledge and management skills that will further strengthen Dechra’s Executive team,” the firm said in a stock exchange statement.

Dechra

A University of Wyoming professor and the Wyoming state veterinarian have received awards from US animal health organizations.

Professor Donal O’Toole of the University of Wyoming’s Department of Veterinary Sciences received the Distinguished Career Service Award from the American Association of Veterinary Laboratory Diagnosticians (AAVLD) at the association’s recent annual meeting in Greensboro, North Carolina.

Prof O’Toole was honored for his long-term service to veterinary diagnostic medicine in the US. This

included peer-reviewed papers, teaching related to diagnostic medicine, service on the association’s executive board, including the presidency in 2005-2006 and as chair of its pathology committee.

State veterinarian Jim Logan received the National Assembly Award from the US Animal Health Association, which met jointly with the AAVLD. The National Assembly is the collaborative body of all US state animal health officials.

Dr Logan was recognized by all state veterinarians for his contributions in advancing animal health programs nationally.

Wyoming vet awards

See page 19 of this issue of Animal Pharm for an overview of China Animal Healthcare’s third-quarter results, in which the company has reported a 10% increase in year-on-year revenues.


10

Feature

Growing stray dog problem encourages zoonotic diseaseThe growing problem of dealing with millions of roaming stray dogs around the world and their many diseases focused the minds of experts attending a major international dog population conference held in the UK recently

Some 170 delegates from 35 countries gathered in York to hear that of the 500-700 million dogs worldwide, 75% are free-roaming, some ownerless but many owned.

Many of these dogs carry diseases such as echinococcosis, leishmaniasis and rabies and are in poor health. Speakers stressed that stray dog population management is an integral part of programs aimed at reducing the risk of dog-based zoonoses, with rabies being the most widespread.

The delegates attending the ‘First International Conference on Dog Population Management’ hosted by the UK government's Food and Environment Research Agency (FERA) were informed that traditional methods of culling these animals under national programs are considered inhumane and ineffective.

More recently, programs to manage populations of dogs and diseases have adopted surgical sterilization in conjunction with vaccination.

This is often in the context of the ‘One Health’ concept whereby animal, human and environmental health are closely linked in national and international strategies.

The main organizer of the conference was Dr Giovanna Massei who is a senior ecologist with FERA. She came up with the idea for the event two years ago, after speaking in Italy about non-lethal means of controlling dog populations to an audience of major players in animal health.

Dr Massei told Animal Pharm: “In recent times there has been considerable opposition from the public to lethal methods of controlling dog populations. Culling is often carried out with inhumane methods that might also affect the environment and non-target species, particularly when toxicants are used. Culling is also opposed by communities, as many free-roaming dogs have owners. In addition, this method reinforces the ‘quick fix’ solution and does not encourage responsible ownership or public commitment to identify humane, publicly acceptable and sustainable solutions to manage dog populations.

“Because I was working on contraceptives to mitigate human-wildlife conflicts, I began to see how the same concept could be applied to free-roaming dog populations. In many instances, reducing the density of dogs could have beneficial effects on the problems caused by dogs, as well as on the welfare of these

animals that are often in a very poor physical condition, particularly in Asia.

“Of course any program aimed at reducing the density of free-roaming dogs will have to receive the support of the local community before it is implemented and will have to be run in conjunction with education and awareness campaigns. I was also concerned that surgical sterilization could be unsustainable mainly due to its costs and requirement for specialized staff and facilities.

“We need some alternatives such as non-surgical sterilization that can be administered more effectively to manage dog populations. The conference brought a number of stakeholders together, including the OIE and WHO, to look at the issues and to discuss perspectives and solutions for dog population management,” noted Dr Massei.

Other co-organisers were the Royal Society for the Prevention of Cruelty to Animals; the World Society for the Protection of Animals; the International fund for Animal Welfare and the Humane Society International.

The conference also brought together representatives of pharmaceutical companies and researchers such as ecologists, modelers and economists. Dr Massei hopes that in the future, vaccination campaigns against rabies might be run in conjunction with community-supported non-surgical sterilants and contraceptives. Current research in this

field aims at bringing these products to market.

The conference heard that to reduce dog populations, female dogs should be targeted although ideally males should also be sterilized. There have been very successful rabies campaigns in South America, Bali and the Philippines – plus a successful dog population control programme in South Africa which led to increased government funding.

“The conference was effective in getting the stakeholders to think and act together in the future and share their knowledge and experiences and we hope it has acted as a catalyst for future programs on dog population management. Cutting down the number of dogs on the street, by combining education on responsible ownership, disease awareness, vaccination and sterilization, is likely to reduce the number of diseases. But it has to be done involving the local community and gaining its support at every stage.

“Ecologists are becoming more involved because they can measure or predict the impact of intervention on dog population size and on disease transmission. Previously, dog control and disease was simply the province of veterinarians and animal health specialists. The input from ecologists will add value to the overall efforts to eliminate diseases and manage animal populations,” said Dr Massei.

The delegates also discussed common problems such as a lack of funding; insufficient political will and corruption

Dr Giovanna Massei


11

and lack of intersectoral cooperation, particularly in the developing world, which can undermine dog population control projects.

At the same time, the OIE encourages the use of combined measures such as responsible ownership including the registration and identification of dogs, plus reproduction control.

Although it is 20 years since India introduced special measures to control its free roaming dog populations, the latter is still a major problem, with rabies remaining a serious issue. The Indian dog plan included catching, sterilizing and vaccinating

over 70% of the stray dog population and returning them to their original locations. Although there have been some notable successes in certain Indian states, the overall picture remains virtually the same as two decades ago. It is estimated that 15 million people a year are bitten in India by rabid dogs, leading to 20,000 rabies associated deaths.

At the same time stakeholders in York heard that pet ownership is increasing rapidly in emerging economies such as China, which has resulted in companion animal problems.

Peng Feng Su of ACTAsia for

Animals noted: “There are no regulations in China to ensure even minimal animal welfare standards. These animals, mainly dogs and cats, are not vaccinated, neutered or even treated with basic standards of care or disease prevention.

“Many of these animals are believed to be sourced from suppliers who maintain breeding factories again with inadequate standards of care. Animals that become sick after being sold are often abandoned, becoming a major source of stray animals. The current standard Chinese government response to cases of human rabies is indiscriminate massive killing of owned and stray animals.”

Between 2006 and 2010 it is estimated that 110,000 dogs in China were put down following human rabies cases. Dog sterilization is a relatively new concept but is gaining popularity with animal agencies is the country.

Delegates were told that it has been estimated that some 55,000 people die from rabies globally each year with some 95% as a result of rabid dog bites. Most of the victims are thought to be children.

Programs combining surgical sterilization and rabies vaccination have been shown to dramatically reduce dog numbers and rabies transmission. l

A French public affairs expert with Ceva Animal Health has been looking at ways to improve the performance of commercial companies in the animal health sector with regards to the global One Health strategy.

Dr Pierre-Marie Borne, Ceva’s public affairs director, said the best way to increase the involvement of the animal health private sector in One Health was to enhance the likelihood of commercial success as a result of a commitment to vaccines and pharmaceutical development. Dr Borne addressed delegates at the recent Global Risk Forum in Davos which highlighted the importance of the global One Health strategy.

Dr Borne said the aim of One Health was to gather all the relevant stakeholders and align their interests to a singular mission regarding animal and human health. He said funds allocated to experimentation and skilled

human resources are the main drivers.

“More innovative vaccines using new technology may also require further specific investment in production. Guaranteed access to a minimum part of the subsequent market would help to create the necessary minimum sustainability of the process. The support could be delivered to partners such as private sector companies and public research institutes where they have developed a vaccine candidate,” said Dr Borne.

He recommended fast track registration to reduce access time and costs to potential vaccines according to national and regional regulations. At the same time he recommended special low rate loans for investment or subsidies when needed.

He also said there should be a minimum guaranteed income through the establishment of reserve vaccine banks for emerging diseases or advance guaranteed vaccine agreements

for lingering diseases.

“Vaccine banks at global or regional level can create leverage effects and facilitate the use of high quality vaccines assuring consistency of vaccination campaigns. This should allow an acceptable value chain for the different partners, a reliable delivery, a rigorous management of flexibility, and facilitate the international supply of vaccines,” noted Dr Borne.

Private sector has ‘huge impact’He said the animal health private sector is a small part of the global health value chain but has a huge impact in helping to secure food supplies, controlling the emergence of disease and ensuring high sanitary levels by preventing the transmission of food borne diseases and zoonoses. The combination of these three actions significantly contributes to the One Health approach.

Dr Borne noted that the

impact of major disease outbreaks on global health, or in economic terms, is always greater than the direct cost on animal production. When dealing with zoonoses, this impact is even higher and integrates a societal aspect.

He told Davos delegates that the animal health market represents only 2.5%/3% of the global human pharma market. On the other hand, the sector will benefit from the global trends in terms of population growth and subsequent protein demand, which will limit the possible volatility of the sector. In 2010·the animal health world market amounted $20,100 million and had increased by 4% from the previous year.

The top 10 companies represented 80% of 2010 global animal health sales whilst the top three accounted for 45%.The top 10 companies invested an average of 8.7% of their sales in research and development in 2010, before regulatory costs. l

Commercial success seen as part of One Health


12

Feature

Why I became an independent animal health consultantby Mick WellsThey looked at me like I had three heads when I told them I was going out on my own. I am sure many of my colleagues still think I’m crazy having left the comfort and security of a large multi-national company to be self-employed. Granted, that is a unique decision in this post-recession era, but not all too uncommon.

But everything had been falling into place. The company that I had spent well over a decade helping to shape was on the verge of a biannual changing of the guard. I had achieved the goals that I had set out to, and had reached the highest level that I could without taking a lateral move.

I had more exposure and benefits from world-class training and post-graduate programs than I could have ever imagined possible. For the last year I even had an executive coach who actually wrote the book on leadership development! I had been developed.

But I was on the road 75% of the time. My kids were in pre-school and I was missing more than I wanted to. When I was in town, I was at the office because I had responsibilities there. At home, after the kids went to bed, I went to my desk to work until late. It was a taxing schedule and I wasn’t alone, millions live that experience every day.

I would turn 40 in a few months and had been with big pharma my whole career; the first part in sales roles, the second half in commercial and operational leadership roles. I had always worked for someone else, never for myself.

It was the middle of the December and my wife and I had taken our customary trip to her native Venezuela, and in between visits with family, we spent quality, reflective time on the islands and in the mountains talking about what was important to us. And, it was decided, I would strike out on my own – it seemed more rational then buying a sports car!

But what was I going to do? Well, I had worked in operations for the last half-dozen years and, after all, this was just building a strategic plan. Only this time it wasn’t just allocation of sales and expense budgets to meet pre-determined earnings guidance. I was building a plan for my own enterprise; I would have final decision based on the earnings I expected.

I decided to go independent and join the ranks of those that author and management consultant expert Peter Drucker refers to as ‘intellectual capital on demand’. A growing number of leaders whose professional experience and skill sets are at a high-level, who are able to keep their knowledge current, but who prefer to take on work with whom they want and with time and travel commitments that they want.

Most, like myself, are refugees from big corporations who value autonomy and the flexibility of temporary or project-based work, and find that the compensation is comparable to what they earned in full-time jobs. For me it promised a better work-life balance; a career could be built on this, and one that afforded time to explore diversifying my value.

Why consultancy?Thankfully the world has made this option very accessible these days.

It’s commonplace to communicate virtually and there are very few limitations; you can have simultaneous conferences in multiple locations, with various presentations, with incredible connectivity. You can share files, presentations and data in a split second and it can be stored safely in the clouds for accessibility.

There are free customer relationship management (CRM), accounting and invoicing platforms complete with their own Apps so you can be utterly mobile. And you can set yourself up on the web and in the world of social media in about three minutes.

Other than the mechanics, it’s become commonplace for companies to use independent workers. More outsourcing and consulting in recent years has accustomed managers to think about work, even high-end work, in a modular way. Knowing how to best engage this low-risk, flexible, and faster talent model has been a source of competitive advantage for organizations trying to increase their earnings.

Also, companies follow talent – especially in Animal Health. So as a growing number of talented professionals decide that they prefer to work independently and on a temporary basis, organizations are finding ways to work with them. It ends up often being easier than hiring a traditional consulting team where junior associates and their own permanent employees do much of the actual work.

Independence – being American, this is a natural tendency. What intellectual capital do I have in this market place and for whom does it provide the most value? Fortunately, about every year during my corporate career I worked with at least one consultant on some project or the other. I’ve learned there is always a clear path forward; you just have to find it. So I began to replay my career to answer those questions.

Who needs strategic support?Over the years, I had assumed roles in consulting projects ranging from being among those from whom the baseline information is sourced to being part of the implementation team; from leading the projects to doing the grunt work.

Once we had a major consulting firm leading a sales optimization project. I was tasked to do a piece of the work and after days planning and analyzing, I had ended up developing the entirety of the go-to-market recommendation, including: days in the field; calls per day; segmentation; reach; and frequency of which client bases. I sent it to the consultant he thanked me, clarified some points, changed the color scheme and font and presented it to the leadership team for approval.

That experience gave me confidence and led me to look at other parts of the commercial side of the business with that


13

same methodology. Ultimately this resulted in the shape of our commercial operations organization, sales policies and procedures, key account and distribution strategies and organizational designs.

From experiences with consultants and support from mentors and bosses I had developed the ability to pull myself back from the day-to-day routine and look objectively at the goals of the organization and business dynamics in which it operates and to recommend a rational path forward to build measured return on the investment. I had been successful at developing commercial strategy.

The animal health world is much bigger than it may appear to many of us in the midst of it. There are marketers and manufacturers in all sectors of healthcare. A handful have their own resources to perform these higher-end projects or have access to prestige consulting firms on retainers with their parent organization.

But there are hundreds whose businesses are smaller and don’t have these luxuries. They are well-run, well-led organizations, with solid and profitable product lines. They have the capabilities and experience to conduct strategic planning but are often challenged by the fixed limitations of headcount, time and cost.

To this group, I can be an extra set of hands at a variable cost to them; one who’s return on investment can be measured. It’s low-risk and the potential to have an objective examination of their business and go-to-market strategy, to explore areas they may not have had the resources to before, is a good value proposition.

Consultancy in animal healthThe animal health consulting business is quite a healthy and intimate community. There are many independents and much intellectual capital on demand.

Many specialize, while some manage the relationships between manufacturers and distributors; others specialize in R&D, registrations, recruiting, data management and marketing services. There are prestige animal health, management consulting firms as well as many horizontal firms that crossed over into the industry from time to time.

Each of these provides rational and objective counsel, as well as help with business planning, and performing higher-end, modular jobs. Consultants can dig deep, with amazing bandwidth, into challenging assignments as this is their sole focus; rather than have a permanent employee take it on as their third or fourth priority.

This enables organizations to take on tasks that might never have been attempted, try more things, test new business ideas fast versus putting together full-blown business plans with permanent staffing commitments. If we explore growth opportunities, their company preserves its flexibility; as the project moves on they can take a decision to scale up or down. This is valuable support.

The market is in flux. Government and non-governmental institutions, and the courts of public opinion are holding sway in both the companion and livestock markets. Shareholders and stakeholders demand increased earnings despite immense challenges: lean management teams; post-recession economy stagnating top-line growth; M&A activity that is complex and competitive; and rapidly shifting dynamics in the market.

Often the solution is to decrease the cost base, which poses its own dilemma – the biggest fixed costs, employees, are often the biggest assets to fuel growth.

These are the same influences that affect businesses of all sizes, including my own. The challenges are many, but I’ve been blessed, we’ve successfully completed some engagements and am in the beginning and middle stages of others. However, it’s early and I don’t have a large established clientele, yet.

Benefits of independenceSo I’m out there, always, can’t rest. That means, when I’m engaged with a client, I still have to reach out to new leads, post on a blog, network, monitor LinkedIn groups and Twitter feeds for intelligence, subscribe to and digest multiple newsletters and newsfeeds each day.

But I get to do it at a much more reasonable pace, on a more balanced schedule. I get to see my family every day, I get to be a chaperone on school trips and pack my kids lunch every day (well, I’m not sure if I actually like that part). I can hang out with my wife, I can spend time with my friends – all of these were luxuries before – and now they’re blessings.

I’m less stressed and have more control of my life, while doing essentially the same thing I did as someone else’s employee. I don’t have it all figured out. But I can make quick adjustments to the business; I can alter strategy without going through an approval process.

The growth of this group of independents is still to be determined. With the interest in the veterinary market as a revenue source there are growing financial interests everywhere – chemical, pharmaceutical, biotech, medtech, agriculture and consumer goods companies are aiming to get in the mix.

This attracts the bigger consulting firms who are assigning associates to specialize in animal health. Some independents will go back with companies; new ones will join the ranks. The industry gets more competitive each year but that’s nothing new.

After all that’s what we all love about animal health – it’s dynamic. That’s where independent and other consulting firms alike, are in good positions, our role is to stand in the center of it all, comprehend the potential impact, and figure how to optimize results for our clients; see the trajectories of the industry without bias or emotion. That intellectual capital will always be in demand. l

Mick Wells is the founder & manager of The Whiteboard Team (www.intothewhiteboard.com), an independent consulting firm specialized in the design and implementation of commercial strategy in Animal Health. He is fluent in both English and Spanish, and prior to founding Whiteboard, held leadership roles in both private and public pharmaceutical companies. He can be followed on Twitter: @mckwlls.

Americas


14

Responding to the ASAS animal health challenge“Never before have producers of animal-based food products faced so many challenges and opportunities,” stated the American Society of Animal Science (ASAS).

What is more, to concentrate thinking and clarify priorities in this regard, the Society has laid down a series of Grand Challenges, with one of them focused on animal health.

The ASAS is over one hundred years old and considers itself “the world leader as the source of scientific information on animal well-being and the contributions of animals to human health”. For animal health, its Grand Challenge is: To optimize the health and productivity of animals in a manner that protects and enhances human health.

Supporting the overall challenge is a set of key questions and expected outcomes, which can be found at the www.asas.org/public-policy/asas-grand-challenges website. As the ASAS pointed out, spending on animal health research is only 7% of that for human health, making clarity of thought essential.

Responding to the ASAS document for Animal Pharm, Dr Randolph Seidler, head of global R&D for Boehringer Ingelheim Animal Health, could find no reason not to continue focusing on infectious diseases. “They are the biggest cause of economic loss for livestock farmers and the major concern for the transfer of pathogens from animals to humans,” he said.

“Vaccines and intelligent vaccination programs, combined with stringent biosecurity, are the key to animal health-

management systems over the next 10 years.”

Where today’s vaccines are inadequate or non-existent, as with African Swine Fever for example, a better understanding of host-pathogen interaction and especially the complex response of the immune system towards pathogens and their virulence factors is critical.

“Conventional R&D approaches have not proven sufficient,” noted Dr Seidler “We will not be able to make new vaccines available unless there is an innovation-friendly environment, a flexible regulatory framework and the political will to use vaccines.” Public acceptance of ‘new technologies’ (industry code for genetic manipulation) will also have to be addressed by all stakeholders.

Human and animal health togetherThe ASAS Grand Challenge emphasized the One Health philosophy of considering animal and human health together. Dr Seidler has no doubt that sound vaccine use and suitable biosecurity measures will inevitably lead to lower antibiotic use, with a consequent diminution in the risk of resistance developing. In addition, he considers that a key objective of new vaccine development should be a reduction in the consumption of microbiologically contaminated meat.

When it comes to understanding the nature of the risk posed to livestock by disease, Dr Seidler believed that more could be done with what we have already.

“Plenty of animal health tools are available for improving animal health, but are not used in the most optimal way,” he said. “Education and training of farmers and even veterinarians is needed to get the most out of the tools available today.”

One of ASAS’s support questions refers to the potential of animal genetics. Dr Jason Lilly of the diverse animal and food safety company Neogen Corporation, whose GeneSeek genomic business is a leader in livestock DNA profiling, took time to consider the challenge. “Genomics has worked well in vertically-integrated sectors such as swine, dairy and poultry,” he observed. “The producer sees the value. Where there is more of a disconnect in the supply chain, as with beef cattle, recognizing what genomics has to offer takes time.”

There are other factors that can help genomics deliver. “US dairy is dominated by Holsteins/Friesians and this breed uniformity made it more cost effective to develop the genetic tools that today help us identify in a few days what used to take years via traditional breeding methods,” he continued. US dairy data has been successfully transferred overseas and profiling is well established in Germany, the Netherlands, Australia and New Zealand. This is not the case for beef where there is far more breed diversity.

Opportunities abound, he concluded. “For beef we have now demonstrated that genomics can tell you which animals will respond well to growth promoters and

different feed rations. I believe that aquaculture, specifically salmon farming, could be the next sector to take advantage of genomic profiling.”

Developing world focus?Professor Andy Peters, the interim CEO of not-for-profit vaccines alliance GALVmed, thought that ASAS’s Challenge does not explicitly address the developing world. “Food security needs to be understood as being very directly linked to economic security in Africa and other parts of the Developing World,” he said.

“Livestock is effectively a ‘bank account’ for, and central to the livelihoods of millions of people. They are a key driver of economic development and need to be considered in the same light as education and infrastructure”.

The emphasis in the Developing World is on health before productivity. So much can be achieved there by the simplest medical interventions, such as worming, that are a given in the West. What is undeniable is that livestock are not meeting their productive potential. While this is partly genetic, it is mostly due to environmental limitations and husbandry systems.

“The ASAS challenges are visions and strategies. GALVmed and other NGOs need to work to implement them at ground level,” said Prof Peters. “We are looking and potentially intervening along the entire value chain from the production of livestock medicines, vaccines and diagnostics, through their development and supply, down to the ‘last mile’. l


15

US maintains funding for FAO avian flu workThe United States Agency for International Development (USAID) will inject $20 million into a Food and Agriculture Organization (FAO) initiative that aims to reduce the spread of avian flu in Southeast Asia.

This deal brings the US’ total contribution to FAO activities in tackling HPAI and other zoonotic diseases to $213m over a period of seven years.

The latest funding is designed

to support the existing US-FAO partnership that aims to tackle H5N1 highly pathogenic avian influenza (HPAI) and widen the focus on potential emerging pandemic threats.

The FAO said that the USAID funding will strengthen its preparedness and response to HPAI in Southeast Asia and bolster laboratory and surveillance capacities in hotspot areas. The funding

will largely be used to support activities in Bangladesh, China, Indonesia and Viet Nam, which currently experience fatal incidences of H5N1 HPAI in poultry and humans.

“Funding will also go to regional coordination to combat avian influenza and to support surveillance and prevention in Cambodia, Lao PDR, Nepal and Myanmar, which are threatened by

the disease’s continuing persistence in neighboring countries,” added the FAO.

“These countries continue to have sporadic outbreaks, indicating the H5N1 virus continues to circulate in poultry and remains a threat to poultry production, human health and the livelihoods of millions of vulnerable farmers who depend on poultry raising for their basic food needs and a means of making a living.” l

Harrisvaccines secures another US vaccine contractIowa-based Harrisvaccines has won its second vaccine development contract with the US government in the space of a month.

The latest $1.14 million contract is with the US Department of Homeland Security and aims to develop a vaccine for foot-and-mouth disease (FMD). Harrisvaccines will create an RNA Particle (RP) vaccine to defend against any potential outbreaks of FMD in the US.

The firm will spend three years developing the product using its RP platform technology, which it claims allows for the vaccine to be manufactured without handling the infectious FMD virus.

“Only a gene sequence from the virus is needed to prepare the vaccine,” explained Harrisvaccines. “This characteristic allows the RP-based FMD vaccine to be produced in Harrisvaccines’ USDA-licensed production facility in Ames. Production of FMD vaccines using traditional methods in the US is not allowed due to the

significant risk of releasing the virus into FMD-free US during production.”

Dr Kurt Kamrud, vice president of research and chief scientific officer at Harrisvaccines, said: “Our rapid response technology allows us to produce large amounts of vaccine quickly. And, because only a portion of the FMD virus genetic information is required to generate a vaccine, the RP-based approach will allow for the differentiation of infected from vaccinated animals when used with current and next-generation FMD serology-based diagnostic assays, which is very important in the event of an outbreak.”

Less than a month ago, Harrisvaccines received US Department of Agriculture approval for a new swine flu vaccine manufactured through its RP technology (Animal Pharm, October 2).

Aside from developing vaccines for the livestock sector, Harrisvaccines is also focused on the aquaculture industry. l

Animal health companies interested in producing and selling generic veterinary medicines in Brazil can now request the registration of new products at the Ministry of Agriculture (MAPA), the body that will be responsible for assessing and authorizing the commercialization of the generic drugs.

MAPA has started receiving applications since the new law to allow the production and use of generic veterinary products in the country came into effect on October 17, three months after it was approved by the Congress and signed up by the president Dilma Roussef (Animal Pharm, News, August 10).

The new law establishes that the companies have to prove the generic product’s bioequivalence to the reference drug; therapeutic equivalence in the species it is indicated for and, in the case of food producing animals, the same withdrawal period, level of

residues and excretion rates as the reference drug.

Detailed technical specifications for the generic drugs are not available yet but, according to MAPA, the document is not necessary at this point of the registration process. It estimates that the specifications will be published in about 60 days.

The Ministry will be responsible for ensuring that the new generic products conform to the law. It will also publish a periodical compilation of all the veterinary products available in Brazil, with their respective names and manufacturers.

There is no expected date for the first generic veterinary drugs to be commercially available. Currently MAPA takes about three years to assess and grant approval s for new veterinary drugs, and there is no estimate on how long the approval process will take in the case of generics. l

Brazil opens registration for generics

Europe

www.animalpharmnews.com

16

New veterinary school for the UK An English university has announced plans for a new veterinary school – the eighth in the UK – with close links to major animal health research facilities in the area and an emphasis on the One Health concept.

The University of Surrey intends to open its School of Veterinary Medicine in 2014, located at its Manor Park site in Guildford in the south east of the country. The University already has strong links with organizations such as the Animal Health and Veterinary Laboratories Agency (AHVLA), the BBSRC Pirbright Institute and the Veterinary Medicines Directorate (VMD) which are also based in the area. It will also work with local veterinary practices and specialists.

There will also be an international dimension to the courses through the University Global Partnership Network (UGPN), a trilateral agreement between Surrey, North Carolina State and São Paulo Universities with teaching collaborations, summer scholarships and research exchanges.

Surrey intends to offer a unique, research-led veterinary medicine degree program with an emphasis on global research, veterinary pathology and livestock medicine. It intends to draw on the University’s science, technology

and business resources in producing well rounded, research veterinarians.

The School will be part of Surrey’s Faculty of Health and Medical Sciences, which will help inform its ‘One Health – One Medicine’ approach. The University already offers a BSc program in Veterinary Biosciences and an MSc in Veterinary Microbiology, with a new MSc in Veterinary Pathology under development. It is consulting with the Royal College of Veterinary Surgeons (RCVS) over a timetabled program to meet the College’s accreditation standards, although the monitoring process could take a number of years.

“This is good news for the UK veterinary research community,” commented Professor John Fazakerley, director of The Pirbright Institute. “The Pirbright Institute currently works in close collaboration with the University of Surrey on research that benefits animal health and welfare; we very much look forward to building on this established and growing association as the new School of Veterinary Medicine is launched. There is an important place for trained veterinarians in scientific research and we are delighted that the University has decided to emphasize these areas in particular.” l

The Finnish food Safety Authority (Evira) said the Schmallenberg virus has been detected in cattle on the Aland Islands between Finland and Sweden in the Baltic Sea.

The Schmallenberg discovery was made on the Aland Islands at the end of September where Evira said antibodies of the virus were discovered.

The virus may have arrived

on the Aland Islands along with midges carrying the virus or with imported ruminants. Schmallenberg was detected in Germany last autumn and had spread as far north as Denmark and Sweden

Evira is also looking at blood samples taken from cattle in the coastal areas of southern and south-western Finland to see if there are any further outbreaks of the virus. l

Schmallenberg discovered in Finnish cattle

The Schmallenberg virus (SBV) has been confirmed in Ireland, the most westerly case of the nine European countries so far found to have the virus.

The Irish Department for Agriculture, Food & Fisheries stated that the first case of SBV in the Republic was discovered on a farm in County Cork in the south of the country.

The Department said it is carrying out tests to establish the source of infection. It is possible that it

is an isolated case.

Since the first reports of the disease in northern Germany in late 2011 (Animal Pharm, November 25 2011) it has been diagnosed in 6,000 animals across nine EU states – Belgium, France, Germany, Italy, Luxembourg, the Netherlands, Spain, the UK and now Ireland.

SBV, usually transmitted by insects, causes abortion and birth defects in calves, lambs and kids born to infected ruminant animals. l

Romanian authorities have detected Newcastle disease on a backyard poultry farm in the central Brasov region.

It is the country's first case of the virus for more than three years and was reported to the World Organisation for Animal Health.

Belarus has already responded by banning imports of poultry-related products from Romania. A series of measures have

been put in place to curb the outbreak, including screening, zoning and disinfection of the affected premises.

Romania exported almost 50,000 tonnes of chicken meat in the first half of 2012, a rise of 20% on last year. Almost half of this total went to Bulgaria, with other important buyers including Hungary, Netherlands, UK and Germany. l

First SBV case in Ireland

Newcastle disease detected in Romania


17

The UK farm ministry Defra has confirmed that a case of Equine Infectious Anaemia (EIA) or ‘Swamp Fever’ has been found in a horse in Cornwall in the south-west of England.

The affected horse will have to be put down. Others at the same stable yard have been put in quarantine and are currently being tested for signs of the disease.

EIA is a viral disease that affects horses, mules and donkeys and is most commonly spread by biting insects such as horse flies. There is no treatment and

horses do not recover from the disease, which can be fatal.

Defra’s chief veterinary officer, Nigel Gibbens, said: “We have confirmed that one horse is infected with EIA. All the necessary precautions to prevent disease spread, including movement restrictions on the sick horse and others at the same stables, were put in place as soon as we became aware of the animal’s illness.

“We have also begun a thorough investigation to ascertain whether any other horses may have been exposed to infection.” l

UK horse found with EIA

US healthcare products distributor Henry Schein is set to make its third acquisition of the year by acquiring Irish firm C&M Vetlink.

Henry Schein has signed a definitive agreement to buy C&M, which is a leading distributor of animal health products in Ireland, for an undisclosed fee.

The acquisition allows Henry Schein to expand its European network to Ireland and, according to the company itself, positions it as the leading Irish animal health distributor.

Limerick-based C&M was founded in 1973 and recorded sales in the 12 months ended July 30 of €42 million ($54.7 million). Around 70% of C&M’s sales are for large animals, which it says reflects the importance of dairy farming and livestock

to the Irish economy. The majority of these sales are pharmaceutical products.

The closing of the acquisition is expected before the end of the year. Henry Schein forecast the deal to be neutral to slightly accretive in its financial results for 2013.

After closing of the deal, C&M’s managing director Edmond Wall and assistant managing director Jim Spratt will take up directorial roles at Henry Schein.

Henry Schein’s two other acquisitions this year were that of Dutch distributor AUV Veterinary Services in April (Animal Pharm, April 11) and UK-based surgical and implants company Veterinary Instrumentation in January (Animal Pharm, January 5). l

Sharp fall in UK antimicrobial sales New figures issued by UK Veterinary Medicines Directorate (VMD) indicate a sharp fall in sales of veterinary antimicrobial products in the country during 2011 compared to the year before.

Total net sales of antimicrobials dropped in 2011 to 346 tonnes from 447 tonnes in 2010. However, the VMD believes most of the sales reduction can be accounted for by specific product sales fluctuations between 2010/2011 as a result of changes in marketing authorizations for different companies.

The VMD said 2011 sales of antibiotic products for use in UK food producing animals accounted for approximately 84% of the total annual sales of 346 tonnes which was comparable with previous years.

They noted that it was not possible to identify the proportion of the 290 tonnes which was administered to food producing animals that did not enter the food chain.

“Overall the sales of veterinary antibiotic products for use in food-producing animals showed a decrease in 2011, from the 2010 sales.

“There was variation in sales of veterinary antibiotic in 2011 for some of the individual food-producing species such as pig and poultry products decreased by 90 tonnes, pig only products increased by 15 tonnes and poultry only

products decreased by 27 tonnes in 2011 compared to 2010.

Sales of cattle only products in 2011 increased by one ton, whilst other species specific products and multispecies product sales revealed little change compared to 2010 sales figures,” said the VMD report.

It added that by antibiotic class between 2006 and 2011 more tetracyclines were sold than any other class. This amounted to 32% of sales.

Some 54% of veterinary antibiotic products for food-producing animals were sold for use as medicated feeding stuff, most of which are sold for use in pig and

poultry farming. The sales of veterinary antiprozals in 2011, were 283 tonnes, an increase of 28 tonnes since 2010.

All veterinary antibiotic products in the UK may be supplied only under veterinary prescription. Sales of antibiotics for veterinary medicinal products for use in non-food producing animals accounted for 35 tonnes or 10% of the annual sales of 346 tonnes.

The VMD said it was reasonable to assume that there is a direct relationship between the amount of antimicrobials sold in the UK and the amount actually used. Total numbers of UK cattle, pigs, sheep and poultry have declined in the last five years. l

Henry Schein makes Irish buy

❝Total net sales of antimicrobials in the UK dropped in 2011 to 346

tonnes from 447 tonnes in 2010❞

World


18

Quality vaccines are key to Chinese market, says Ceva expertChina’s huge number of food-producing animals means that it faces an array of infections which cannot be defeated by inconsistent or sub-standard veterinary vaccines and antimicrobials

Dr Steve Chu, vice president, global biology research and development for Ceva Animal Health, says quality vaccines and sound animal health management are needed.

Speaking to Animal Pharm in Budapest, the China-born animal health expert said the country needs quality products so that it can deal with the problems faced in the rapidly expanding animal health sector.

“The pharmaceutical companies need to be part of the solution. They need to train Chinese scientists and have quality products and sustain the effort. Ceva can be part of the process and achieve good business results. We can provide economic animal health solutions and avoid waste. Quality pharmaceutical products, not cheap ones should be the driving force behind animal health. Quality plus efficiency side by side is the way to achieve the goal we want,” said Dr Chu.

“However, animal health products in China are not consistent and need tighter

control. This means that there is an opportunity for pathogens to find ways to persist and escape immunity. This makes better management more critical. And it is not only important that China is seen as part of the problem, but that it should be part of the solution.”

In fact Dr Chu, who has 30 years animal health experience, said he was cautiously optimistic because some animal diseases in China have already been eradicated. Equine anemia for example has already become rare in China.

The Chinese government is investing heavily in the Harbin Research Institute and the Shanghai Veterinary Institute. In addition, it is sending researchers to the United States and other countries to improve standards and to make a contribution to the country’s animal health sector. Collaboration with foreign countries regarding veterinary health has also been useful.

Backyard pigsThe Kansas-based specialist said China was the biggest swine producer in the world. However, a significant number of these animals are backyard pigs, which meant a great deal of interaction between the pigs and humans. Pig diseases in China include PRRS, diarrhea disease problems, swine fever and pseudorabies.

“The Chinese government is trying to manage the animal disease scenario. It is trying to improve the quality of the vaccines and antimicrobials.

While vaccines are only part of the disease control scenario, the government is in fact making progress, but more is needed. It needs to improve technology and upgrade the production methods for vaccines. Consistency of both the animal health product and its quality is needed. From batch to batch quality is vital,” noted Dr Chu.

As regards the poultry sector in China, the main diseases are avian influenza, Newcastle disease and infectious bronchitis. Ruminants, although a smaller market than swine and poultry, are an important source of food in China.

Ruminant diseases include foot and mouth disease, viral respiratory disease and Brucellosis. Dr Chu said all the mentioned diseases are important to China and the Beijing animal health authorities should continue working hard to control or eradicate them.

“Eradication with certain major animal diseases is achievable and Chinese investment in novel solutions, vaccines and technology would create animal health opportunities. Chinese animal health can upgrade and it will benefit the rest of the world if it does so,” Dr Chu concluded.

Joint venture Given the importance of future growth in China and the rest of the Asian region, Marc Prikazsky, Ceva’s chief executive has personally led the group’s expansion there. The company directly

entered the market with the establishment of a joint venture Ceva Huadu at the end of last year (Animal Pharm, July 11 2011).

“If you enter a joint venture in China you will have to take some risks. A contract is only paper,” said Dr Prikazsky.

“The aim should be to make a profit from the beginning, otherwise the relationship is probably wrongly balanced. We are very pleased with the first year’s results. Currently, we have some 200 people employed in China and we intend to invest even more in people and technology.”

He added that Ceva plans to double the company’s annual research and development investment globally from around €50 million ($64 million) to €100m ($129m). This would help the group to contribute towards two of its mission objectives: helping feed a growing population with safe, quality animal protein and helping combat emerging zoonotic diseases. l

Dr Steve Chu

Dr Marc Prikazsky


19

FMD vaccines boost China Animal Healthcare revenueChina Animal Healthcare has recorded healthy year-on-year revenue gains in its third fiscal quarter, as sales went up 10% to CNY228.7 million ($36.6 million).

During the first nine months of the year, revenues climbed 16% year-on-year to CNY643.2m. The firm said that revenues were boosted by strong performances from its biological drug division (+37% to CNY83.8m) and powdered drugs segment (+60% to CNY136.5m).

The company’s vaccines against foot-and-mouth disease (FMD) have also proved to be very profitable. Sales of the firm’s range of FMD vaccines reached

CNY93m during the first nine months of 2012, compared to CNY23.1m in the same period last year.

Sales of vaccines for porcine reproductive and respiratory syndrome were up during the period and offset a dip in revenue from swine fever vaccines.

Net profit for the third quarter was up 6% to CNY56.5m, while during the first nine months of 2012 it dropped by 14% to CNY147.7m.

“We are encouraged by the results achieved for 9M2012 despite months of incessant cynicism confronting the convalescing Chinese economy. We expect revenue

contribution from the sales of mandatory vaccines to continue strongly into the last quarter of the current financial year,” said Wang Yangang, the company’s chairman, executive director and chief executive.

He added: “The Group has obtained indicative orders from 23 provinces and municipalities for its swine fever vaccines, PRRS vaccines and animal FMD vaccines of approximately CNY10m, CNY50m and CNY60m respectively.

These orders are expected to be fulfilled over the next six to twelve months upon sales confirmation. The prospects of the animal FMD vaccines

remain highly promising.”

China Animal Healthcare expects to remain profitable with strong growth in the current financial year.

The firm specializes in the manufacture, sale and distribution of 452 compound chemical drugs and 44 biological drugs for poultry and livestock in China. The group also produces 37 feed additive products.

The company sells to around 4,900 animal drug retailers and 32 large poultry enterprises in China and through government tenders to various regional government animal disease control centers. l

More than 650 delegates attended the recent Leman Swine Conference, held in Xi'an in central China, for the first time outside the US.

The University of Minnesota College of Veterinary Medicine was responsible for bringing the Leman Swine Conference to China with the support of Northwestern A&F University. The event has been described as the world's largest annual pig education event and is the first time it has been held in China.

One of the organizers, Dr Frank Liu of the University of Minnesota said: “The delegates included 100 companies from 10 different countries, mostly from China. The conference also hosted 25 exhibitors and a poster session. This first Leman China Conference was very

well received and considered the best organized swine conference for the past decade in China.

The two-day meeting covered various topics on pig production, disease management, nutrition, and panel discussions delivered by 15 speakers from North America and China.”

Dr Liu added that the event aimed to promote the University’s missions of education, research and outreach through providing science-driven solutions to the global swine industry. The organizing committee hopes to visit China more regularly with the conference.

The Leman event has a 27-year history and is normally held in the US. China is the world’s largest pig producing country. l

The international animal health and nutrition company Alltech has entered into a number of research alliances with leading Chinese universities and research institutions.

Lexington, Kentucky-based Alltech said the joint working groups at each Chinese university will focus on specific emerging challenges to animal agriculture in China.

The company, which recently had a signing ceremony in Beijing to mark its new Chinese research strategy, has linked up with the Chinese Academy of Agricultural Sciences; Zhejiang University; South China Agricultural University; Northwest A&F University and Jiangnan University. Alltech’s 2011 survey (Animal Pharm October 31) showed that

China is now the largest feed market in the world.

Dr Lyons said: “Issues such as mycotoxins, feed and food safety and the environmental impact of our industry are strongly present in China. Also, in times of the highest ever raw material prices in history, Chinese animal producers still need to be profitable by reducing feed costs and increasing animal performance. One of the biggest questions for China is how the country can improve the feed conversion rate and at the same time decrease its dependence on crop imports.

“Alltech’s investment of more than $2.5 million to the Chinese research alliances in the next five years clearly indicates our commitment to find sustainable solutions to these challenges.” l

Alltech in research pact with China

First Leman pig conference in China

2020

Diary

Conferences, courses and meetingsNovember

13-14 November

A One Health Approach to Antimicrobial Use and Resistance – a National Institute for Animal Agriculture symposium, Columbus, Ohio, USwww.AnimalAgriculture.org

16-18 November

33rd Annual Meeting of Japanese Society of Veterinary Medicine, Osaka, Japanwww.dorinken.com

27-28 November

World Animal Health Congress 2012, Kansas City, USwww.terrapinn.com

December

5-9 December

CVC San Diego, California, USwww.thecvc.com

January 2013

4-6 January

17th Federation of the Asian Veterinary Associations (FAVA) Congress, Taipei, Taiwan

www.2013favacongress.com

19-23 January

North American Veterinary Conference (NAVC), Orlando, Florida, IS

www.NAVC.com

February

9-11 February

Annual conference of the Japan Veterinary Medical Association, Osaka, Japan

www.jvma2013.jp

15-18 February

4th International Meeting on Emerging Diseases and their Surveillance (IMED), Vienna, Austria

http://imed.isis.org

18-22 February

International Sheep Veterinary Congress, Rotorua, New Zealandhttp://conference.intsheepvetassoc.org

21-22 February

International Workshop on Veterinary Pharmacovigilance for Global Food Security, Madras, IndiaMore details via: [email protected]

March

6-9 March

The 38th World Small Animal Veterinary Association Congress, Auckland, New Zealandwww.wsava2013.com

13-15 March

OIE Global Conference on the Prudent Use of Antimicrobial Agents for Animals, Paris, Francewww.oie.int

13-15 March

VIV Asia 2013, Bangkok, Thailand – includes the VIV Animal Health Summit Asia

www.vivasia.nl

13-15 March

Aquatic Asia 2013, Bangkok, Thailand

www.aquatic-asia.net

26-28th March

VETME: Middle East Veterinary Trade Exhibition and Conference, Dubai, UAE

www.vetmiddleeast.com

April

4-7 April

British Small Animal Veterinary Association (BSAVA) Congress, Birmingham, UK

www.bsava.com

Buyer’s Guide

Head office: Vetnosis, Abbey House, 83 Princes Street, Edinburgh EH2 2ER UKOffice: +44 (0)131 718 0772 E-mail:[email protected] Web www.vetnosis.comVetnosis (formerly Wood Mackenzie) is a leading commercial research and consulting firm specialising in global animal health and veterinary medicine. Built on the strength of 25 years research and analysis, Vetnosis publishes a unique portfolio of independent, authoritative and insightful research reports, tools and databases that are trusted resources for the leading companies. Vetnosis publishes more than 120 research reports within the ANIMAL HEALTH SERVICE, including Company profiles and datasets; Country datasets and profiles; Product Group and Species reports; Outlook reports; and quarterly tracking study. Our proprietary forecasting tool, STORM FORECASTS, delivers granular 10-year animal health, animal agriculture and macro-economic forecasts for 58 countries/regions. vPAT-Online is a proprietary online database of licensed veterinary medicines and animal health products in 11 key countries. It covers 37,000+ products and 700+ animal health companies and is a unique and powerful tool for business development, competitive intelligence and R&D.

CRO

IT Man

ufac

ture

rRe

gula

tory

Information at a glance

•

Tel: +44 (0)1875 614545 Fax: +44 (0)1875 614555 www.criver.com Email [email protected]

Charles River has been supporting the development of animal health products for over 40 years. Our full portfolio of target animal, preclinical and clinical studies includes absorption, distribution, metabolism and excretion (ADME), pharmacokinetic, bioequivalence, residue depletion and target animal safety studies.

With facilities in Europe and North America, we offer a comprehensive, global service to the animal health industry.

•


Mar

ket R

esea

rch


21212121

•

CRO

IT Man

ufac

ture

rRe

gula

tory

Mar

ket R

esea

rch

Produkt + Markt, Otto-Lilienthal-Str. 15, D-49134 Wallenhorst, GERMANYContact: Karl-Georg Herbert, Tel: 0049-5407-885-212, Email: [email protected], www.pundm.deDeep understanding of markets and customers – that’s what we stand for since 1970. PRODUKT + MARKT has extensive experience in animal health and agribusiness marketing research. With our interdisciplinary team we provide outstanding expertise for the lifestock and companion animal markets of the world. Reliable – actionable – cost effective. Give us a call to explore the opportunities.

Head office: GfK Kynetec, Weston Court, Weston, Newbury, Berkshire, RG 20 8JE, UK

Tel mobile (559) 917-4005. Contact: [email protected]; www.gfk-kynetec

GfK Growth from KnowledgeFor more than 50 years, GfK’s Animal Health has provided syndicated and custom research solutions to the world’s animal health and pet food industries. Through our profound experience, we have gained a strong understanding of the key issues facing our stakeholders across geographies and the expertise to provide answers that work.

• •

•• •

TRIVERITAS (Head Office: Bank Barn, How Mill, Brampton, Cumbria, CA8 9JY, UK).+44 (0) 845 123 2888 [email protected] www.triveritas.comTriveritas, your expert partner in Animal Health. Offices in UK, France, Germany and USA delivering tailored global solutions using local knowledge. Our team of vets and scientists have in-depth global experience in development and registration of veterinary biologicals & pharmaceuticals. Our flexible approach uses innovative strategies addressing timelines and budget. Expertise includes: Full Product Development; VICH GCP Clinical Studies; Regulatory Affairs; Strategic Advice; Quality Assurance (GxP); Training; Project Management. ………helping you succeed.


KLIFOVET AG, Geyerspergerstr. 27, D-80689 München, Germany. Tel: +49-89-5800820. Fax: +49-89-58008215. Contact: Dr. Klaus Hellmann. www.klifovet.comBased in the centre of Europe, thinking globally. The CRO for the development of veterinary medicinal products, feed additives and borderline products. Full program development services, regulatory affairs, electronic submissions, substantiation of efficacy claims, quality compliant safety (GLP) and efficacy studies (GCP) in all animal species, supported by GMP compliant test product management, quality assurance and data management services. Special expertise in the assessment of antimicrobial properties (MIC), business development services. Test our dedicated services or purchase STUDYBASE®, the validated study management software.

•• •Quality in Animal Health

••

•• ••

ONDAX Scientific UK, Horsham, England Tel: +44 1403 788 285ONDAX Scientific HQ, Hondarribia, Guipuzcoa, Spain Tel: +34 943646087 [email protected]; www.ondax-scientific.com

ONDAX Scientific, the European Specialists in Clinical Trials (pharmaceutical and biological) to the animal health industry. Our services include: test permits, study set-up, monitoring, quality assurance, data management, statistical analysis and reporting both for companion animal and livestock.

GAB Consulting GmbH – Hinter den Höfen 24, 21769 Lamstedt, Germany – Fon: ++49 / 4773 / 88 89-0, Fax: ++49 / 4773 / 88 89-20 – [email protected] - http://www.gab-consult.de

GAB Consulting GmbH is active in the area of veterinary medicines’ approvals. We offer qualified services in the development, optimization and registration of veterinary medicines, based on current regulations. • Years of industry experience in the development of veterinary medicines including vaccines • Reliable support in the development of products or regulatory strategies • Thorough care of laboratory and field tests and evaluation of experimental data • Close contact with authorities • Multiple services under one roof • Vaccine quality, safety and efficacy trials • Pharmaceutical pre-clinical and clinical development •ERA • Scientific writing

••

•

Veterinary Research Management Ltd, Stoney Lodge, Upper Street, Kingsdown, Kent, CT14 8DT Tel: +44 (0)7768 357402 Email: [email protected] Website: www.vrm.uk.com A specialist research management company with proven project management expertise to accelerate your development project (pharmaceutical or vaccine) to regulatory approval. Working synergistically with clients from proof of concept to registration, we execute existing plans or develop innovative new ones. VRM Ltd also represents both, Ridgeway Research Ltd, UK and Veterinary Health Research Pty. Ltd, Australia. With direct access to these two world class test facilities in the northern and southern hemispheres and an expert team of interdisciplinary scientists, our services include: • Project management from formulation to approval • Global experience in registration of new entities and generics • Dose optimisation • GLP compliant test facilities • Target animal safety, efficacy, tissue residue, bioequivalence and pK studies in livestock and companion animals • Parasiticide studies including helminths, coccidia and ectoparasites • Supply of Fasciola hepatica metacercariae, various nematodes and field coccidian strains • Multi-country field studies • Expert report writing and regulatory defence • Full integration of the 3 Rs •

TSGE T: +44 (0) 1423 799 633 E: [email protected] www.TSGEurope.com TSGE - A leading European regulatory consulting company, TSGE’s scientific, regulatory and registration specialists are actively engaged in obtaining and defending product registrations across Europe. With offices located in the UK, Ireland, Germany, Spain and Slovenia, our specialists can prepare biopesticide active substance and product dossiers including assessments of human health and environmental risk in the areas of plant protection and public health. TSGE also successfully participates in and manages task forces and consortia.TSG - TSG provides state, federal and international expertise on a wide range of scientific and regulatory issues throughout North America. With experts in regulatory affairs, chemistry, toxicology, environmental fate and risk assessment, TSG provides services in support of the development, registration, compliance and defence of biopesticides. Our clients include pesticide, fertiliser, chemical, consumer product, food, personal care and animal health companies, as well as industry groups, trade associations and law firms.

• •

Buyer’s Guide

Mar

ket R

esea

rch

ESTENDART LIMITED, Aviation Way, Poultry Farm Road, Palmerston North 4442 New Zealand. Tel: +64 (0) 6 3500770 Email: [email protected] www.estendart.comEstendart Ltd is NZ’s leading company for regulatory-based studies conducted to GLP (OECD) and GCP (VICH) standards. Estendart Ltd (est 1986) is alongside Massey University’s Vet School with direct access to the extensive research facilities, farms and veterinary expertise. Proof-of-concept, pre-clinical and clinical studies (multi-site) are undertaken in all food-producing and companion animals. These focus on efficacy, safety and residue (food-producing) evaluations. Services include animal models for the evaluation of medical devices and determination of the toxicology of compounds with biological activity. Estendart provides a full service commencing with arranging the importation of test items, protocol development, quality assurance, statistical analysis and reporting. All studies comply with NZ law on animal welfare. Although based “downunder” we are still only a dotcom away.

22


222222

Buyer’s Guide


CRO

IT Busin

ess S

ervi

ces

Regu

lato

ryM

arke

t Res

earc

h

MB Consult Limited, Enterprise House, Ocean Village, Southampton, Hampshire SO14 3XB

Tel: 02380 574560 Email: [email protected] website: www.mbconsult.com

MB Consult is an international provider of expert microbiological advice to a range of industries. With extensive experience, MB Consult has an enviable track record within the veterinary pharmaceutical and animal feed industries. We are closely involved with microbiological issues high on the agenda of CVMP and CVM. Offering microbiological dossier preparation, risk assessment, analysis of data and reports and study planning, we can work with you to meet regulatory guidelines.

• ••

• •

ADAS at Drayton, Alcester Road, Stratford-on-Avon, Warwickshire, CV37 9RQ Tel: 01789 293057 Fax: 01789 414393 Website: www.adas.co.uk

Choose ADAS as your specialist farm animal health CRO and our expert research team will deliver your project to the highest standards of quality, confidentiality and satisfaction. Based in the heart of the UK, our offer includes:

• Cattle, sheep, pigs, poultry and horses • GLP and GCPv compliance • Target Animal Safety and efficacy for veterinary pharmaceuticals and vaccines • Viral and bacterial challenge • Residue studies including pharmaceuticals and pesticide animal transfer • Parasitology studies • Feed micro ingredient safety and efficacy studies Send an email to [email protected] to request a brochure, or a phone call from our specialist client team.

• ••

• •

CEBIPHAR, 1 rue de la Bodinière, 37230 Fondettes, France – Tel : +33 (0)2 47 42 48 48, Fax : +33(0)2 47 42 03 28 Web: www.cebiphar.com Email: [email protected].

CEBIPHAR is an independent CRO which has over 30 years of experience in product development for the animal health industry. We provide a wide range of services: analytical development, stability studies, microbiology, QC, safety, PK, residues, experimental models, GCP clinical field studies and regulatory affairs. Besides, our subsidiary Cebiphar Formulation Services developed a specific know-how on veterinary dosage forms coupled with a strong expertise in formulation patents. Our laboratories and facilities are GMP and GLP certified.

Farma Research Animal Health B.V., Toernooiveld 300-H, 6525 EC Nijmegen, the Netherlands. Tel: +31(0)24 350 55 74 Email: [email protected] Web: www.frah.nl Contact: Hans van Hattum.

Farma Research Animal Health B.V. is an independent, GLP accredited, CRO. More than 20 years we are specialised in the performance and organisation of veterinary projects:

• In-life phase: dog, cat, (dairy) cattle, sheep, horse, pig, poultry. • Bio-analytics: in plasma, tissues, milk, egg, etc. • Regulatory affairs: consultancy, dossiers, expert reports

Farma Research Animal Health B.V. is a small, flexible organisation with short communication lines.

2 St. Pauls Road, Clifton, Bristol BS8 1LT, UK Contact: Phil McGuire Tel: 0117 973 9036 Fax: 0117 973 8958 Email: [email protected] Web: www.cyton.com

Cyton is the leading European veterinary regulatory affairs consultancy providing specialist product development and registration services to the global animal health industry. From proof of concept through to registration and beyond, Cyton provides expertise in depth. Cyton covers all therapeutic classes, target animal species, product types and delivery routes, including pharmaceuticals, vaccines, biologicals, immunologicals, feed additives, pharmacovigilance and MRL dossiers.

•

• •

Vetspin S.r.l. Via Tolara di Sopra, 50, 40064 Ozzano dell’Emilia (BO), Italy Tel: +39 (0)51 2097500 Website: www.vetspin.com Email: [email protected]

Vetspin performs GLP safety and GCP efficacy studies on farm animals, including cattle, pig, sheep, poultry and rabbit. • Target animal safety, pharmacokinetic, residue depletion, dose determination in infected animals. • Development and validation of analytical methods for veterinary drugs on plasma, tissues (liver, kidney, fat, fat+skin, muscle, other tissues), milk, eggs, manure. • Data Analysis (Biostatistics). • Dossiers and Expert Reports.

•

2323


2323

Who does what...

Animal Pharm No 745

Subscription Enquiries: (North and South America) Contact: Yoram StoneTel: +1-212-6525369Email: [email protected]

(Rest of world) Contact: Alessandro CattaniTel: +44 (20) 7017 7353Email: [email protected]

Subscription RatesUK £1,090 Europe €1,650 North America US$2,260

General EnquiriesEmail: [email protected]: +44 (0)20 7017 5540 or (US) Toll Free: +1 800 997 3892

Online AccessEmail: [email protected]: +44 (0)20 7017 4161

ADVERTISINGAdvertising Ben WatkinsAccount ManagerTel: +44 20 3377 3911Email: [email protected]

Mechanical Requirements (size in mm, depth x width) Full page (260 x 185) Half-page horizontal (128 x 185) Half-page vertical (260 x 88) Quarter-page horizontal (62 x 185) Quarter-page vertical (128 x 88) Eighth-page horizontal (62 x 88)

COMMUNICATIONSAnimal Pharm Editorial119 Farringdon Road, London, EC1 3DA, UK.

Tel: +44 20 7017 6840 Fax: +44 20 7017 6838 Email: [email protected]

US Office52 Vanderbilt, 16th Floor, New York, NY 10017, US. Tel: +1 212 520 2789

Japanese SalesT Hirata, Shiryo Kenkyujo, 3-6-5-904 Sotokanda, Chiyoda-ku, Tokyo 101, Japan.

Tel: +81 3 3258 9207 Fax: +81 3 3258 9209 Email: [email protected] tlx: 2655207.

ORDERING AND PAYING

Ordering and payments (which should be made payable to Animal Pharm) can either be transacted through:

1. UK Head Office – payment by sterling cheque drawn on a UK bank or by a sterling Eurocheque, or Visa, Mastercard, or American Express.

2. The US Office – payment by US dollar cheque drawn on a US bank, or American Express.

3. The Japanese Sales Agent – payment by a Yen cheque drawn on a Japanese bank made payable to Shiryo Kenkyujo.

4. Companies ordering Bookshop Reports regularly may open credit accounts. For details, please contact the Reports sales office at the UK Head Office.

ANIMAL PHARM ONLINEAnimal Pharm is available online. http://www.animalpharmnews.com/aboutus/ For full details contact: Lucy Salter Tel: +44 (20) 701 75312 Fax: +44 (0)20 7017 6985 Email: [email protected]

CONDITIONS OF SUPPLYThis publication is supplied on the following conditions:

1. All rights reserved: no part of this publication may be stored in a retrieval system, abstracted, reproduced, distributed or transmitted (which in each case includes doing so in any form or by any means, electronic, mechanical, photocopying, recording or otherwise) without the prior written permission of the publisher, or under the terms of a licence issued by the Copyright Licensing Agency whose address is 90 Tottenham Court Road, London W1P 9HE, UK or rights organisations in other countries that have reciprocal agreements with the Copyright Licensing Agency

2. It may not without the prior written permission of the publisher be exported, distributed or circulated outside the staff who work at the address to which it is sent by the publisher

3. While due care has been used in compiling this information, the publisher makes no claim that it is free of error or fit for any particular purpose and to the fullest extent permitted by law SPECIFICALLY DISCLAIMS ALL OTHER WARRANTIES (EXPRESS OR IMPLIED) INCLUDING BUT NOT LIMITED TO ANY IMPLIED WARRANTY OF QUALITY OR FITNESS FOR ANY PARTICULAR PURPOSE. In addition the publisher does not accept liability to anyone for the consequences of any decision or action taken (or which any person refrains from taking) in reliance on any information contained herein

4. Further terms and conditions apply to any contract under which this publication is supplied and are available from the publisher on request.

*Periodicals Postage Paid at Rahway NJ. US Postmaster send address corrections to Animal Pharm c/o Mercury Airfreight International Ltd Inc., 2323 Randolph Avenue, Avenel, New Jersey 07001, US.*

Registered Office Mortimer House, 37/41 Mortimer Street, London, W1T 3JH, UK.

Registered in England No 1275302 and printed in the United Kingdom by MPG impressions Ltd, Units E1-E4, Barwell Business Park, Leatherhead Road, Chessington, Surrey KT9 2NY, UK

© Informa UK Ltd 2012: All rights reserved. ISSN 0262-2238

Anju Ghangurde Correspondent (India) Tel: +91 22 3294 1543 Email: [email protected]

Nathalie CapletCorrespondent (France) Tel: +33 (0) 678 15 51 94Email: [email protected]

Jamie DayEditor (UK & EU)Tel: +44 20 7017 6840Email: [email protected]

Dr Atsuo HataCorrespondent (Japan) Tel: +81 6 6854 4851Email: [email protected]

Ben WatkinsAccount ManagerTel: +44 20 3377 3911Email: [email protected]

Malcolm FlanaganAsia Editor (China & South East Asia)Tel: +44 20 7017 7547Email: [email protected]

Katharine AskewProductionTel: +44 20 7017 6820Email: [email protected]

Joseph HarveySenior Reporter (US & Latin America)Tel: +44 20 7017 7392Email: [email protected]

A not-for-profit global alliance, GALVmed (Global Alliance for Livestock Veterinary Medicines) is working to make livestock vaccines, medicines and diagnostics accessible and affordable to the millions in developing countries for whom livestock is central to livelihood.

This exciting new, senior management role of Market Development & Access Director will provide direction, skills and “thought leadership” in all aspects of market development, promotion mechanisms and supply chains that enable poor livestock keepers to access high quality animal health products.

Suitably qualified, experienced and committed individuals are invited to review the job description: http://www.galvmed.org/about-galvmed/vacancies-1/

To discuss the role, please contact: Professor Andy Peters, Interim CEO: [email protected] Application is by CV with a covering letter outlining your interest in the role to Sharon Ross, HR Manager: [email protected]

Closing Date by which applications must be received: midnight GMT (Greenwich Mean Time) 16th November 2012.

Market Development & Access Director

Competitive salary – dependent on experience

Based primarily in United Kingdom, with significant international travel

A not-for-profit global alliance, GALVmed (Global Alliance for Livestock Veterinary Medicines) is working to make livestock vaccines, medicines and diagnostics accessible and affordable to the millions in developing countries for whom livestock is central to livelihood.

This exciting new, senior management role of Market Development & Access Director will provide direction, skills and “thought leadership” in all aspects of market development, promotion mechanisms and supply chains that enable poor livestock keepers to access high quality animal health products.

Suitably qualified, experienced and committed individuals are invited to review the job description:http://www.galvmed.org/about-galvmed/vacancies-1/

To discuss the role, please contact: Professor Andy Peters, Interim CEO:[email protected] Application is by CV with a covering letter outlining your interest in the role to Sharon Ross, HR Manager:[email protected]

Closing Date by which applications must be received: midnight BST (British Summer Time) 16th November 2012.

REGIONAL TECHNICAL SERVICES DIRECTOR

£ Excellent Plus SeniorManagement Benefits

Home Based coveringEurope & EMEA Region

Our Client is a world leader in manufacturing and delivering customised antimicrobial & production efficiency solutions to the animal feed & primarylivestock production industries in over 60 countries around the world. With over 35 years’ experience, the company has developed a range of top qualityproducts supported by the best specialists in the industry. A multi-million pound turnover business, they have seen revenues grow by 20% year on yearover the last 5 years and have strategically invested in R&D programmes which have built a robust pipeline of exciting new products that will furtherenhance their worldwide offering, including recent launches of new products for the Pet Food sector and the Bio-fuels industries.

An exciting opportunity now exists for a commercially focused technical specialist to join the organisation and play a key role in providing technicalsupport across the EMEA region to key customers, sales staff and distributors. This will include managing product evaluation, interpreting and providingdata for sales and marketing teams, as well as being the commercial bridge between R & D and customers across industry sectors covering LivestockProduction, Animal Feeds and Primary Meat and Egg Processing.

As a technically competent individual, possessing a strong academic base, including being educated to masters and doctoral level (ideally PhD) in ascientific, life science or agricultural based subject area, you will possess a base of post education business exposure, ideally in a commercially focusedarea. Alternatively, you may have studied veterinary medicine (hold DVM status) and have complemented this with commercial business experience.Previous exposure to areas of animal nutrition or feed additives would be an advantage. In any event, you will possess technical competence and the abilityto manage and drive projects, absorb technical information and impart this through effective communication, as well as making an effective contributionto the development and launching of new product ranges. Additionally, you will possess excellent written and spoken English and the capability ofcommunicating effectively throughout all levels of business.

This is a home based role and will involve regular travel throughout Europe, the Middle East and Africa (EMEA), therefore, being a current passport holderand having and a willingness to travel are essential. In return, you will receive an excellent base salary package, together with a Senior Management Bonusand Benefits Package and have the opportunity to develop a first rate career in a successful, established and growing organisation.

We operate as retained recruitment specialists for our Client, therefore, please forward an up to date CV, quoting Ref: 2518/AP, quoting yourcurrent or previous base salary, to Paul Collingridge – Managing Director, The Collingridge Consultancy Limited, Moreby Grange, Moreby,York, YO19 6HN. Email: [email protected] Tel: 07977 131177

ap 745

Documents

hendra vaccine

pfizer animal health

spread of hendra virus

world animal health

pfizer australia

horse vaccine

deadly hendra horse

health challengepage